エピソード

  • Oncology Unscripted With John Marshall: Episode 33: When Dogs Detect Cancer

    Oncology Unscripted With John Marshall: Episode 33: When Dogs Detect Cancer
    2026/07/29

    Main Topic
    In this episode of Oncology Unscripted, Dr Marshall examines the evolving role of blood-based cancer screening and highlights new research showing how dogs may help detect early cancers from breath samples.

    Alternative Data Centers, Medicine, and AI Guilt?
    In MedBuzz, Dr Marshall discusses the emergence of betting on clinical trial outcomes, the rise of AI in medicine, the environmental impact of data centers, and whether growing reliance on artificial intelligence should leave clinicians with a sense of AI guilt.


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    続きを読む 一部表示
    14 分
  • Oncology Unscripted With John Marshall: Episode 32: Post-ASCO Roundup: RAS, Research, and the Road Ahead

    Oncology Unscripted With John Marshall: Episode 32: Post-ASCO Roundup: RAS, Research, and the Road Ahead
    2026/06/29

    Main Topic:
    In this episode of Oncology Unscripted, Dr John Marshall discusses major post-ASCO developments in GI oncology, including new RAS inhibitor data in pancreatic cancer and the path forward.

    MedBuzz:
    In this episode of Oncology Unscripted, Dr John Marshall reflects on a trip to South Africa and what it revealed about survival, inequity, and the luxury of modern cancer care. Through experiences in Johannesburg and on safari, he connects cancer care access to broader questions of privilege, community, and responsibility.

    Interview:
    In this episode of Oncology Unscripted, Dr John Marshall speaks with global oncology experts about cancer care access and the barriers that limit availability of new treatments and testing worldwide. The discussion examines drug pricing, reimbursement, value, and the need for more equitable access to cancer care.


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    続きを読む 一部表示
    40 分
  • Oncology Unscripted With John Marshall: Episode 31: ASCO 2026 Preview: Precision Medicine, MRD, and the Next Wave of Care

    Oncology Unscripted With John Marshall: Episode 31: ASCO 2026 Preview: Precision Medicine, MRD, and the Next Wave of Care
    2026/05/27

    MedBuzz:
    In this episode of Oncology Unscripted, John Marshall, MD, discusses a troubling week in health care news, including upheaval at the FDA, concerns about reduced federal support for medical education, and growing evidence that AI-generated fabricated references are appearing in published scientific literature.

    Main Topic:
    In this episode of Oncology Unscripted, Dr John Marshall previews the practice-changing data expected at ASCO 2026, highlighting advances in precision medicine. Tune in to hear which presentations could shape the next wave of cancer care.


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    続きを読む 一部表示
    12 分
  • Oncology Unscripted With John Marshall: Episode 30: Navigating the Expanding Role of Precision Medicine

    Oncology Unscripted With John Marshall: Episode 30: Navigating the Expanding Role of Precision Medicine
    2026/05/21

    MedBuzz:
    In this episode of Oncology Unscripted MedBuzz, Dr Marshall discusses evolving rectal cancer data and the growing role of genomic testing. He also reflects on US science policy and concerns about instability, and the need to modernize clinical trials while protecting independent oversight and patient data.

    Main Topic:
    In this episode of Oncology Unscripted, Dr Marshall discusses the growing role of precision medicine in oncology and how it is shifting from an optional tool to a standard part of cancer care, including the increasing importance of MRD and ctDNA, and promise of blood-based cancer screening.

    Interview:
    In this episode of Candid Conversations , Dr. John Marshall speaks with Dr. Marija Balic of UPMC and the University of Pittsburgh about MRD ctDNA testing in early breast cancer.


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    続きを読む 一部表示
    32 分
  • Oncology Unscripted With John Marshall: Episode 29: AI in Cancer Care: Promise, Pressure, and the Physician’s Role

    Oncology Unscripted With John Marshall: Episode 29: AI in Cancer Care: Promise, Pressure, and the Physician’s Role
    2026/04/29

    MedBuzz:
    In this MedBuzz, Dr John Marshall discusses Steve Ubl’s departure from PhRMA and what it may signal for drug pricing, pharmaceutical policy, payer dynamics, and patient access.

    Main Topic:
    In this episode of Oncology Unscripted, Dr John Marshall explores the growing role of AI in cancer care, from analyzing patient data and predicting treatment responses to supporting clinical trials, guidelines, manuscripts, and patient communication. He also reflects on the risks of AI, including privacy, bias, accountability, energy demands, and the potential loss of human connection in medicine.

    Interview:
    In this expert panel discussion of Oncology Unscripted, Dr John Marshall explores how artificial intelligence is being used in health care today and where it may be headed next. Guests Neel Trivedi, MD; Ross Filice, MD; and Torbjørn Furuseth, MD, discuss AI scribes, radiology, digital pathology, clinical decision-making, patient privacy, and the ongoing role of human judgment in medicine.


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    続きを読む 一部表示
    38 分
  • Oncology Unscripted With John Marshall: Episode 28: Are We Watching a Global Evolution in Cancer Care Leadership?

    Oncology Unscripted With John Marshall: Episode 28: Are We Watching a Global Evolution in Cancer Care Leadership?
    2026/03/25

    MedBuzz:
    After a trip to the Galapagos, Dr John Marshall reflects on evolution in nature, cancer, and medicine. From Darwin’s observations to the rise of AI and precision oncology, he explores how rapidly cancer adapts, how technology is reshaping care, and why the future of medicine must still preserve the human touch.

    Main Topic:
    In this episode of Oncology Unscripted, Dr John Marshall reflects on a practice-changing cholangiocarcinoma study from China and what it reveals about the rapid evolution of cancer research worldwide. As novel therapies transform care and China expands its investment in science while the US devests, he asks whether we can keep pace and the impacts of the global evolution of in oncology.

    Interview:
    Watch now as Dr John Marshall sits down with Dr Louis Weiner, director of Georgetown University’s Lombardi Cancer Center, for a candid conversation about leadership, scientific change, and the future of oncology. Reflecting on innovation, institutional transition, and the pressures reshaping cancer research, they explore what it means to evolve as a leader and honoring the work and the people.


    Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
    続きを読む 一部表示
    30 分
  • Oncology Unscripted With John Marshall: Episode 27: Groundhog Day, The Ice Palace, and $25 Trillion Cancer Costs

    Oncology Unscripted With John Marshall: Episode 27: Groundhog Day, The Ice Palace, and $25 Trillion Cancer Costs
    2026/02/23
    MedBuzz: Watch now as Dr Marshall discusses the growing instability at the FDA, including job cuts, leadership turnover, and structural reorganization. Main Topic: This episode of Oncology Unscripted explores the projected $25 trillion global cost of cancer care, rising cancer incidence, and declining mortality, all set against political and funding uncertainty in frozen Washington, DC. Interview: In this episode of Oncology Unscripted, John Marshall, MD, sits down with Richard Pazdur, MD, former director of the FDA’s Oncology Center of Excellence, for a candid discussion about his transition to and from the FDA, reflecting on what’s been built and what is at risk of being lost. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.
    続きを読む 一部表示
    33 分
  • Oncology Unscripted With John Marshall: Episode 26: Microbes, Mutagens, and Mortality: CRC in a Younger Generation

    Oncology Unscripted With John Marshall: Episode 26: Microbes, Mutagens, and Mortality: CRC in a Younger Generation
    2026/01/28
    Oncology Unscripted at ASCO GI: People, Pipelines, and PrecisionJohn Marshall, MD:Hello, everybody, from San Francisco, California. My name is Dr. John Marshall, and you are on—maybe unwisely—Oncology Unscripted. But thanks for joining me. I love this meeting, but let's first talk about the news of 2026.Top of the line is: we're out to get new countries. Now, I'm sort of running for mayor of Havana. I don't know if it's important that I, in fact, speak Spanish—because I don't. I speak a little bit of French. My Spanish is terrible. But maybe it won't matter, because I am who I am, and they're looking for just my kind of person to go be mayor of Havana. So, if you see that and you get a chance to vote, vote me in. I love the whole country of Cuba—it's beautiful.Second, in today's newspaper—I couldn't believe it—this guy named Dr. Oz, you know him, he's an actual cardiologist, believe it or not. Then he became the talk show host. And then, for some reason, he's the head of CMS at this point—one of the head overseers of healthcare here in the country. And he said his position was that alcohol is good. This couldn’t have made me happier. This couldn’t have been a better holiday present, because I'm a big alcohol fan myself, and now I can feel less guilty about it. His rationale is that if you drink more, you'll be with people more, you'll be more relaxed, and the camaraderie will pay off in terms of lessening your anxiety and stress—and the world will be a happier place.So, don’t be smart. We don't want people in our country to be intelligent or educated. Drink more. Be less educated. You'll be happier in the long run. That's the official position of our government today.Probably the most important new news from a healthcare perspective is that the House approved an extension on the Affordable Care Act. This has been an incredible threat and uncertainty for so many of our patients. The people who depend on that health insurance could never afford cancer care without it. Having the extension of the Affordable Care Act—for them—talk about lowering your stress. Maybe better than alcohol is actually being insured.I don’t know if you go to many meetings out there, but this one is called GI ASCO. It's always in San Francisco. It's always in this building that I'm standing in now. I have perfect attendance. I’ve been to every one since they started. You should get a special ribbon for that. I think there’s probably one down there for that.They are a little bit more environmentally conscious—no plastic covering to this. Just a piece of paper. Totally recyclable old name badge. Way to go, ASCO, on that.Do you go to meetings or don’t you? I come to this one for a very, very important reason. I come to this one for the people. It’s a small meeting. It’s just the GI gang, both from the industry side and the academic side. It’s a very heavy global presence that comes. I know almost everybody here, and there are only like 3,000 people here. There’s time to stop and say hello to almost everybody you know—give them a hug, share a little COVID, maybe flu, with each other—but then know that you are connected again. And this is something Zoom doesn’t do. This is something you can’t check on—somebody’s kids—over a meeting. But that’s one of the main reasons I come.I love these people. These are people that share in our values and our motivation to try and cure cancer. We all take care of the group of cancers—GI cancers—which are the most common, most fatal cancers on our planet. We are inspired to do this. We know it’s a steep climb, and we do it together. I’m so very pleased to be a part of this community, and it’s the main reason I come.Main reason—people. Second reason—pipelines. There’s a lot of data out there, and there are a lot of companies here that finally have new products for GI cancers. We’ll talk a little bit about that in more specific detail, but if you just look at the number of groups that are here—the number of people who’ve got innovative, new approaches—whether it’s novel immunotherapy, targeted agents, combinations of those, targeted antibodies that are delivering toxic payloads—we’re seeing waterfall plots that we haven’t seen in decades.So, response rates, survivals, progression-free survivals that really compare favorably to our traditional chemotherapy approaches. We are on the cusp of a true revolution in the world of GI cancer.And, surprisingly, one more—led by the world of pancreatic cancer. So, let’s talk a little bit about precision in GI oncology. The biggest breakthroughs that we are seeing at this meeting have to do with RAS targeting.There are a bunch of RAS drugs out there now. There are some that are more out in front than others. There are some that are degraders that break down the RAS. There are some that block pan-RAS, so they hit a bunch of RAS targets. There are some that are very specific ...
    続きを読む 一部表示
    34 分